Investment Rating - The report assigns a "Buy" rating for Li Ning (02331.HK) as it is expected to outperform the market in the coming months [1]. Core Insights - The company has demonstrated strong growth in professional categories and improved operational efficiency, leading to better-than-expected performance [3]. - For 2026, the outlook is positive with anticipated revenue growth in the high single digits and a maintained high net profit margin, reflecting management's confidence in brand development [3]. - The forecast for net profit for 2026-2028 has been revised upwards, with expected values of 30.6 billion, 33.0 billion, and 35.6 billion respectively, corresponding to P/E ratios of 16, 15, and 14 [3]. Financial Projections - Total revenue is projected to reach 28.68 billion in 2024, with a year-on-year growth of 3.90%, and is expected to grow to 37.23 billion by 2028, reflecting an 8.11% increase [1]. - The net profit attributable to shareholders is forecasted to be 3.01 billion in 2024, with a slight decline in 2025 to 2.94 billion, before recovering to 3.56 billion by 2028 [1]. - The latest diluted EPS is expected to be 1.17 in 2024, gradually increasing to 1.38 by 2028 [1]. - The P/E ratio is projected to decrease from 16.19 in 2024 to 13.68 in 2028, indicating potential value appreciation [1]. Market Data - The closing price is reported at 21.44 HKD, with a market capitalization of approximately 48.72 billion HKD [6]. - The stock has a price-to-book ratio of 1.76 and has seen a 52-week range between 13.50 and 23.42 HKD [6]. Operational Highlights - The company has successfully controlled sales expenses, leading to a net profit margin of 9.9% in 2025, despite a slight decline in gross margin to 49.0% [9]. - The professional categories, including running and badminton, have shown significant growth, with badminton revenue increasing by 30% and outdoor revenue by 113% [9]. - The company has maintained a healthy inventory level with a turnover ratio of four months, ensuring efficient cash flow management [9].

Investment Rating - The report maintains a "Buy" recommendation for 康哲药业 (0867.HK) with a current stock price of 13.59 HKD [1][3]. Core Insights - 康哲药业's revenue for 2025 reached 82.12 billion CNY, representing a year-on-year growth of 9.9%. The normalized annual profit was 17.76 billion CNY, showing a growth of 3.6% after excluding a one-time tax payment of 2.79 billion CNY [4][7]. - The company is experiencing a harvest period for its innovative products, with sales from core innovative and exclusive drugs reaching 56.13 billion CNY, a growth of 23.3% [7][8]. - The company is accelerating its innovation and research, with two new drugs approved for market release in early 2026, contributing to its growth strategy [7][8]. Financial Summary - Revenue projections for 康哲药业 are as follows: 98.33 billion CNY in 2026, 116.45 billion CNY in 2027, and 139.43 billion CNY in 2028, with growth rates of 19.7%, 18.4%, and 19.7% respectively [6][8]. - Net profit estimates are projected at 19.79 billion CNY for 2026, 22.80 billion CNY for 2027, and 27.16 billion CNY for 2028, with growth rates of 32.9%, 15.2%, and 19.1% respectively [6][8]. - The gross margin is expected to stabilize around 72.5% in 2026, with a net margin of 19.8% [6][8].

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase exceeding 15% over the next six months [9]. Core Insights - The company reported a 3.2% year-on-year increase in revenue for 2025, reaching 29.6 billion RMB, while net profit attributable to shareholders decreased by 2.6% to 2.94 billion RMB [2][4]. - Revenue growth was steady, with footwear, apparel, and equipment & accessories categories showing year-on-year increases of 2.4%, 2.3%, and 12.7% respectively [3]. - The company continues to optimize its store strategy, with a net decrease of 26 sales points to 6091, while maintaining a focus on single-store optimization [3]. Financial Summary - The gross profit margin slightly declined by 0.4 percentage points to 49%, attributed to a decrease in direct sales channel revenue proportion and increased discounts in a volatile consumer environment [4]. - The company plans to distribute a dividend of 0.5695 RMB per share, maintaining a payout ratio of 50% [4]. - Forecasts for 2026-2028 indicate expected revenue growth of 7.6%, 6.1%, and 5.7% respectively, with net profit growth of 4.6%, 11.3%, and 10% [4][10].

Investment Rating - The report maintains a "Buy" rating for Tencent Holdings [1][10]. Core Insights - Tencent's Q4 2025 results met expectations with revenue of 194.4 billion RMB, a year-on-year increase of 13%, and adjusted net profit of 64.7 billion RMB, up 17% year-on-year [7][10]. - The company plans to increase its investment in AI, with a significant focus on new product launches in 2026 [10]. - The report highlights strong growth in enterprise services and advertising, with advertising revenue increasing by 17% year-on-year in Q4 2025 [10]. Financial Data and Profit Forecast - Revenue projections for Tencent are as follows: - 2024: 660.3 billion RMB - 2025: 751.8 billion RMB - 2026E: 834.2 billion RMB - 2027E: 921.4 billion RMB - 2028E: 1,000.8 billion RMB - Year-on-year growth rates for revenue are projected at 8.4% for 2024, 13.9% for 2025, and 11.0% for 2026 [9][13]. - Adjusted net profit forecasts are: - 2024: 222.7 billion RMB - 2025: 259.6 billion RMB - 2026E: 284.0 billion RMB - 2027E: 325.1 billion RMB - 2028E: 365.7 billion RMB - The report anticipates a decrease in the adjusted net profit for 2026 and 2027 due to increased AI investments [10][12]. Valuation - The target price for Tencent is set at 740 HKD, representing a potential upside of 46% from the closing price on March 20 [10][12]. - The SOTP (Sum of the Parts) valuation method estimates Tencent's total market value at approximately 59.3 billion RMB [12].

Investment Rating - The report maintains an "Accumulate" rating for the company [1][7]. Core Insights - The company achieved its first quarterly profit in Q4 2025, with revenue and delivery volumes reaching historical highs. Given the accelerated product iteration and the launch of the "dual-energy vehicle" new car cycle, the "Accumulate" rating is upheld [2][11]. Financial Summary - Total revenue is projected to grow from 40.87 billion RMB in 2024 to 76.72 billion RMB in 2025, reflecting an 88% increase. By 2028, revenue is expected to reach 143.82 billion RMB, with a growth rate of 11% [5]. - Gross profit is forecasted to increase from 5.85 billion RMB in 2024 to 14.47 billion RMB in 2025, with net profit expected to improve from a loss of 5.79 billion RMB in 2024 to a loss of 1.14 billion RMB in 2025, and turning positive in 2027 with a net profit of 1.33 billion RMB [5][13]. - The company’s comprehensive gross margin reached 21.3% in Q4 2025, an increase of 6.9 percentage points year-on-year and 1.2 percentage points quarter-on-quarter [11]. Delivery and Revenue Performance - In Q4 2025, the company reported revenue of 22.25 billion RMB, a year-on-year increase of 38% and a quarter-on-quarter increase of 9%. The delivery volume reached 116,000 units, up 149% year-on-year [11]. - The average revenue per vehicle in Q4 2025 was 164,000 RMB, showing a slight increase compared to previous periods [11]. Strategic Developments - The company has deepened its strategic collaboration with Volkswagen, which has become the first customer for the second-generation VLA architecture. The self-developed Turing AI chip has also been designated for use by Volkswagen [11]. - The company has made significant progress in its overseas business, with over 45,000 units delivered internationally in 2025, marking a 95.6% year-on-year increase. The company has expanded its global presence to 60 countries and regions, with 380 overseas stores [11]. Future Outlook - For Q1 2026, the company expects a delivery volume of 61,000 to 66,000 units, representing a year-on-year decline of 30% to 35%. Revenue is anticipated to be between 12.2 billion RMB and 13.28 billion RMB, a year-on-year decrease of 16% to 23% [11].

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [5]. Core Insights - The company is a leading player in the mid-priced ready-to-drink tea market, focusing on rapid store expansion through a franchise model and regional densification strategy, with over 11,179 stores across more than 200 cities in China as of mid-2025 [1][12]. - The ready-to-drink tea market in China is experiencing significant growth, with the number of consumers increasing from 224.8 million in 2018 to an estimated 482.7 million by 2028, reflecting a CAGR of 7.3% [2]. - The company has established a robust self-built cold chain and logistics system, enhancing supply efficiency and supporting its franchise ecosystem [3]. Company Overview - The company has transitioned from a single-store operation to a franchise management system since its first store opened in 2010, with a focus on regional market penetration [12]. - As of mid-2025, the company has a significant presence in lower-tier cities, with 81% of its stores located in second-tier cities and below [17]. Industry Analysis - The ready-to-drink beverage industry in China is projected to grow from approximately 517.5 billion yuan in 2023 to 627.9 billion yuan in 2024, with a CAGR of about 22.5% from 2018 to 2023 [32]. - The ready-to-drink tea segment is the largest within the ready-to-drink beverage market, accounting for 50% of the market share in 2023 [32]. Competitive Advantages - The company has developed a comprehensive supply chain and logistics system that is closely integrated with its regional densification strategy, allowing for cost-effective supply to franchisees [3]. - The franchise model is supported by a strong management system that ensures high profitability and quick return on investment for franchisees [3]. Financial Projections - The company is expected to achieve revenues of 128.08 billion yuan, 159.74 billion yuan, and 192.23 billion yuan for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 45.7%, 24.7%, and 20.3% [3].

Investment Rating - The report maintains a "Buy" rating for the company [5]. Core Insights - The company reported a revenue of $567 million for 2025, representing a year-on-year increase of 24.9%, and a net profit of $121 million, up 27.4% year-on-year [1]. - All product categories experienced both volume and price growth, with notable performance in the Latin American market, where sales growth exceeded 100% [1]. - The gross margin improved by 0.7 percentage points to 35.9%, driven by favorable currency exchange rates and enhanced market penetration in emerging markets [2]. - The company is expected to continue its growth trajectory, particularly in Africa and Latin America, with projected net profits of $144 million, $172 million, and $202 million for 2026, 2027, and 2028, respectively [3]. Financial Performance - Revenue by product for 2025: Diapers at $450 million (+23.1% YoY), Sanitary Napkins at $100 million (+27.9% YoY), and Wet Wipes at $20 million (+53.8% YoY) [1]. - Revenue by region for 2025: East Africa (+23.9%), West Africa (+18.4%), Central Africa (+34.5%), and Latin America (+134.3%) [1]. - The company’s sales expense ratio, administrative expense ratio, and R&D expense ratio remained stable, contributing to a net profit margin increase to 21.4% [2]. Future Outlook - The company is well-positioned to enhance its market share in Africa and is actively expanding into high-growth regions such as Latin America and Central Asia [2]. - The forecasted earnings per share (EPS) for 2026, 2027, and 2028 are $0.23, $0.28, and $0.32, respectively, with corresponding price-to-earnings (P/E) ratios of 16.5, 13.8, and 11.8 [3].

Investment Rating - The report assigns a negative outlook for Sinopec, indicating that the 2025 performance is expected to be 19% lower than market consensus [2][3]. Core Insights - Sinopec's net profit for 2025 is projected at 32.5 billion yuan, a 34% year-on-year decline, and significantly below market expectations [3]. - The fourth quarter of 2025 showed a meager net profit of 400 million yuan, down 89% year-on-year and 95% quarter-on-quarter, primarily due to a 7.35 billion yuan inventory loss from falling oil prices [3]. - The downstream segments, including refining, marketing, and chemicals, have all weakened, with the marketing segment turning to a loss and the chemicals segment's losses tripling [4]. - The escalating situation in the Middle East is expected to impact Sinopec's downstream operations significantly, with potential supply disruptions in the second quarter of 2026 [5]. Summary by Sections Financial Performance - Sinopec's 2025 net profit is forecasted at 32.5 billion yuan, a 34% decrease from the previous year and 19% lower than market consensus [3]. - The fourth quarter of 2025 recorded a net profit of 400 million yuan, a drastic decline of 89% year-on-year and 95% quarter-on-quarter, largely due to inventory losses [3]. Downstream Operations - All three major downstream segments (refining, marketing, chemicals) showed deterioration in the fourth quarter of 2025, with the marketing segment reporting a loss and the chemicals segment's losses expanding significantly [4]. - The exploration and production segment remained relatively stable, with a 15% decline in earnings before interest and taxes [4]. Market Conditions - The report highlights that the Middle East situation could lead to significant supply disruptions, impacting Sinopec's operations and potentially leading to a shortage of refined products [5]. - The report notes that as the largest downstream operator in China/Asia, Sinopec may face substantial operational pressures due to these geopolitical developments [5].

Investment Rating - The report maintains a "Buy" rating for Chow Tai Fook (1929.HK) with a target price of HKD 13.66, compared to the current price of HKD 11.18 [6][13]. Core Insights - Chow Tai Fook, founded in 1929 and listed in 2011, has a strong heritage and is primarily focused on the jewelry retail and wholesale business, with significant revenue coming from mainland China [22][23]. - The company experienced a revenue decline of 17.5% year-on-year to HKD 89.656 billion in FY2025, with a net profit decrease of 9.0% to HKD 5.916 billion [24][4]. - The company is undergoing a transformation by optimizing its store network and focusing on high-end markets, with a notable reduction in the number of stores due to weak consumer demand [4][36]. Summary by Sections Company Overview - Chow Tai Fook is the largest gold jewelry company in China, with a concentrated ownership structure primarily held by the Cheng family [22][38]. - The company operates multiple brands and has a dual-channel strategy of direct sales and franchising to cover a wide market [23]. Historical Performance - The company's performance can be divided into three phases: 1. FY2012-2017: Revenue and net profit CAGR of -2.0% and -4.5%, respectively, with steady store expansion [2][44]. 2. FY2018-2024: Revenue and net profit CAGR of +10.6% and +8.0%, respectively, driven by franchise expansion [2][54]. 3. FY2025 to present: Store closures and revenue decline due to market challenges, with a focus on improving store efficiency [2][4]. Market Trends - The gold jewelry market is experiencing a shift towards younger consumers, with new segments like ancient gold and national trends gaining traction [3][16]. - The overall market for gold products in China is projected to reach HKD 568.8 billion by 2024, with ancient gold's market share expected to grow significantly [3][16]. Product Performance - The company’s pricing jewelry segment is showing strong growth, with a revenue contribution of 14.6% in FY2025, while the weight-based pricing segment is declining [3][19]. - Signature product lines are being developed to enhance brand differentiation and appeal to mid-to-high-end consumers [3][19]. Store Network and Strategy - The company is reducing its store count, with a net decrease of 833 stores in FY2025 and further reductions expected in FY2026 [4][36]. - Chow Tai Fook is focusing on high-end city layouts and opening new flagship stores to enhance brand attractiveness [4][36]. Financial Forecast and Valuation - The report forecasts revenues of HKD 93.345 billion, HKD 98.380 billion, and HKD 103.276 billion for FY2026, FY2027, and FY2028, respectively, with corresponding net profits of HKD 8.131 billion, HKD 8.980 billion, and HKD 9.547 billion [4][13]. - The estimated EPS for the same period is projected to be HKD 0.82, HKD 0.91, and HKD 0.97, with P/E ratios of 14, 12, and 12 times [4][13].

Investment Rating - The report assigns a "Buy" rating with a target price of HKD 32.42, indicating a potential upside from the current price of HKD 21.98 [4]. Core Insights - The company's performance in 2025 met expectations, with total revenue of USD 548 million, a year-on-year decline of 13%. The oncology/immunology segment generated USD 286 million, down 21% year-on-year. The net profit for 2025 was USD 457 million, bolstered by a USD 416 million after-tax gain from the sale of non-core joint venture stakes [8][14]. - The FRUZAQLA product, marketed by Takeda, showed strong growth in overseas markets with sales of USD 366 million, a 25% increase year-on-year. However, domestic sales of the drug declined by 13% to USD 100.1 million [8][25]. - The ATTC platform has entered clinical trial phases, with multiple drug candidates progressing through various stages of development. The first candidate, HMPL-A251, began global Phase I/II trials in December 2025 for treating advanced or metastatic solid tumors [19][22]. Summary by Sections Performance Review - The report highlights that the 2025 performance was in line with expectations, with total revenue of USD 548 million and a net profit of USD 457 million. The decline in revenue was attributed to challenges in the oncology/immunology segment [8][14]. Clinical Pipeline and ATTC Platform - The clinical pipeline is rich with catalysts, including the ongoing trials for drugs like Sazetidine and Furuzanib, which are expected to expand market opportunities. The ATTC platform has successfully completed its multi-target clinical layout, with several candidates entering trials [15][19]. Earnings Forecast and Investment Recommendations - The report forecasts earnings per share (EPS) of USD 0.07, USD 0.08, and USD 0.13 for 2026, 2027, and 2028, respectively. The discounted cash flow (DCF) method suggests a fair value of HKD 32.42 per share, supporting the "Buy" rating [10][30].